Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.

Vennegoor A, Rispens T, Strijbis EM, Seewann A, Uitdehaag BM, Balk LJ, Barkhof F, Polman CH, Wolbink G, Killestein J.

Mult Scler. 2013 Apr;19(5):593-600. doi: 10.1177/1352458512460604. Epub 2012 Sep 19.

PMID:
22992450
2.

Natalizumab therapy for highly active pediatric multiple sclerosis.

Kornek B, Aboul-Enein F, Rostasy K, Milos RI, Steiner I, Penzien J, Hellwig K, Pitarokoili K, Storm van's Gravesande K, Karenfort M, Blaschek A, Meyer A, Seidl R, Debelic D, Vass K, Prayer D, Kristoferitsch W, Bayas A.

JAMA Neurol. 2013 Apr;70(4):469-75. doi: 10.1001/jamaneurol.2013.923.

PMID:
23420110
3.

Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.

Prosperini L, Giannì C, Barletta V, Mancinelli C, Fubelli F, Borriello G, Pozzilli C.

J Neurol Sci. 2012 Dec 15;323(1-2):104-12. doi: 10.1016/j.jns.2012.08.027. Epub 2012 Sep 21.

PMID:
23006974
4.

Prediction of antibody persistency from antibody titres to natalizumab.

Jensen PE, Koch-Henriksen N, Sellebjerg F, Sørensen PS.

Mult Scler. 2012 Oct;18(10):1493-9. Epub 2012 Mar 27.

PMID:
22454098
5.

Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab.

Sørensen PS, Jensen PE, Haghikia A, Lundkvist M, Vedeler C, Sellebjerg F, Koch-Henriksen N, Fogdell-Hahn A, Myhr KM, Hillert J, Gold R.

Mult Scler. 2011 Sep;17(9):1074-8. doi: 10.1177/1352458511404271. Epub 2011 Apr 20.

PMID:
21511692
6.

Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.

Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A.

Neurology. 2012 May 29;78(22):1736-42. doi: 10.1212/WNL.0b013e3182583022. Epub 2012 May 16.

PMID:
22592369
7.

An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis.

Horga A, Castillo J, Rio J, Tintore M, Auger C, Sastre-Garriga J, Edo MC, Perez-Miralles F, Tur C, Nos C, Huerga E, Comabella M, Rovira A, Montalban X.

Rev Neurol. 2011 Mar 16;52(6):321-30. English, Spanish.

8.

Characterization of anti-natalizumab antibodies in multiple sclerosis patients.

Lundkvist M, Engdahl E, Holmén C, Movérare R, Olsson T, Hillert J, Fogdell-Hahn A.

Mult Scler. 2013 May;19(6):757-64. doi: 10.1177/1352458512462920. Epub 2012 Oct 8.

PMID:
23045379
9.

Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months.

Oliver B, Fernández O, Orpez T, Alvarenga MP, Pinto-Medel MJ, Guerrero M, León A, López-Madrona JC, Maldonado-Sánchez R, García-León JA, Luque G, Fernández V, Leyva L.

Mult Scler. 2011 Mar;17(3):368-71. doi: 10.1177/1352458510385508. Epub 2010 Dec 21.

PMID:
21177326
10.

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, Kappos L, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Lublin FD, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators.

Neurology. 2007 Oct 2;69(14):1391-403. Epub 2007 Aug 29.

PMID:
17761550
11.

Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.

Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S; European Interferon Beta-1a IM Dose-Comparison Study Investigators.

Neurology. 2005 Jul 12;65(1):40-7.

PMID:
16009883
12.

Immunological markers of optimal response to natalizumab in multiple sclerosis.

Villar LM, García-Sánchez MI, Costa-Frossard L, Espiño M, Roldán E, Páramo D, Lucas M, Izquierdo G, Álvarez-Cermeño JC.

Arch Neurol. 2012 Feb;69(2):191-7. doi: 10.1001/archneurol.2011.971.

PMID:
22332187
13.

Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.

Lanzillo R, Quarantelli M, Bonavita S, Ventrella G, Lus G, Vacca G, Prinster A, Orefice G, Tedeschi G, Brescia Morra V.

Acta Neurol Scand. 2012 Nov;126(5):306-14. doi: 10.1111/j.1600-0404.2011.01622.x. Epub 2011 Nov 23.

PMID:
22107083
14.

Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis.

Fernández-Megía MJ, Casanova B, Magraner MJ, Font-Noguera I, Poveda-Andrés JL.

Farm Hosp. 2011 Mar-Apr;35(2):75-9. doi: 10.1016/j.farma.2010.02.003. Epub 2010 Aug 3. English, Spanish.

PMID:
20685144
15.

Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.

Pachner AR, Cadavid D, Wolansky L, Skurnick J.

Neurology. 2009 Nov 3;73(18):1485-92. doi: 10.1212/WNL.0b013e3181bf9919.

PMID:
19884576
16.

CD49d expression as a promising biomarker to monitor natalizumab efficacy.

Defer G, Mariotte D, Derache N, Toutirais O, Legros H, Cauquelin B, Le Mauff B.

J Neurol Sci. 2012 Mar 15;314(1-2):138-42. doi: 10.1016/j.jns.2011.10.005. Epub 2011 Nov 1.

PMID:
22050952
17.

[Rare case of no effective therapy with natalizumab (tisabri) in a female patient with multiple sclerosis and neutralizing antibodies to the drug].

Iakushina TI, Eliseev IuV, Kotov SV.

Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(2 Pt 2):83-6. Russian. No abstract available.

PMID:
23528600
18.

A giant MS plaque mimicking PML during natalizumab treatment.

Twyman C, Berger JR.

J Neurol Sci. 2010 Apr 15;291(1-2):110-3. doi: 10.1016/j.jns.2010.01.001. Epub 2010 Feb 7.

PMID:
20144466
19.

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P; RESTORE.

Neurology. 2014 Apr 29;82(17):1491-8. doi: 10.1212/WNL.0000000000000355. Epub 2014 Mar 28. Erratum in: Neurology. 2015 Feb 24;84(8):862. multiple investigator names added.

20.

Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.

Rinaldi F, Calabrese M, Seppi D, Puthenparampil M, Perini P, Gallo P.

Mult Scler. 2012 Dec;18(12):1760-7. doi: 10.1177/1352458512447704. Epub 2012 May 8.

PMID:
22570359

Supplemental Content

Support Center